Topical antibacterial therapy for acute rhinosinusitis

S.V. Ryazansev¹, A.A. Krivopalov¹, S.A. Eremin¹, G.P. Zakharova¹, V.V. Shabalin¹, P.A. Shamkina¹, A.V. Chufistova²

¹Saint-Petersburg Institute of Ear, Nose, Throat and Speech, Saint-Petersburg

²North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg

Aim: to study the clinical efficacy, tolerability and safety of framycetin in combination therapy of acute rhinosinusitis.

Patients and Methods: 30 patients aged 18 to 68 years were diagnosed with acute rhinosinusitis of moderate degree. The patients included in the study were randomized into 2 groups (n = 15 each). In the main group, topical antibacterial therapy for acute rhinosinusitis was conducted with TRAMICENT^® nasal spray (international nonproprietary name (INN): framycetin, Solopharm, Saint-Petersburg). IZOFRA^® (INN: framycetin, Laboratoires BOUCHARA-RECORDATI, France) was used in the control group. In both groups, patients also received standard therapy for rhinosinusitis (antibiotic therapy, nasal lavage with isotonic saline solutions, symptomatic therapy). The study included 3 visits to an ENT-specialist with an interval between visits of 5–7 days. The treatment effect was evaluated by comparing statistical scores of symptom severity based on patient diaries and clinical follow-up protocols. The ciliary beat frequency was assessed using biomicroscopy before and by 5–7 days from the treatment initiation.

Results: there was a good tolerance of framycetin drugs for topical therapy. No adverse events were registered. Comparative intergroup assessment of local topical antibacterial therapy efficacy with framycetin solution revealed the most marked and statistically significant dynamics of motor activity recovery in the ciliated epithelium in the main  group in which framycetin was of local production. In both groups, there was a significant decrease in the symptoms severity according to clinical follow-up and patient diaries. In the main group receiving locally produced framycetin, the symptoms relief was statistically significantly more marked than in the control group.

Conclusion: the obtained results allow recommending TRAMICENT^® (framycetin, Solopharm, Saint-Petersburg) — a spray for topical administration, dosed for use in otorhinolaryngological practice for the treatment of rhinosinusitis as part of combined therapy.

Keywords: otorhinolaryngology, acute rhinosinusitis, spray, ciliated epithelium, topical therapy, framycetin, Tramicent.

For citation: Ryazansev S.V., Krivopalov A.A., Eremin S.A. et al. Topical antibacterial therapy for acute rhinosinusitis. RMJ. 2020;4:2–7.